• linkedin
  • Increase Font
  • Sharebar

    Prostate Ca: Site of metastases impacts prognosis

    In a study of 8,820 men with metastatic castration-resistant prostate cancer (mCRPC), researchers found the prognosis differs substantially based on where the cancer has spread.

    Andrew J. Armstrong, MD, ScMDr. ArmstrongSpread to the liver is associated with shorter survival than lung and bone spread, and patients with lymph node metastases only have the best overall survival, according to co-author Andrew Armstrong MD, ScM, of Duke Cancer Institute, Durham, NC.

    “This study may help in risk stratification and decision making around the need for chemotherapy or future clinical trials,” Dr. Armstrong told Urology Times.

    Prior reports suggesting the site of metastasis is an important predictor of overall survival of men with metastatic prostate cancer were based on a limited number of patients. This new study is based on a substantial sample of men who received docetaxel (Taxotere) chemotherapy in nine phase III trials, according to the study’s abstract.

    Read: PCa agent detects 97% of lesions when paired with PET

    The authors categorized the sites of metastases as lymph node only, bone with or without lymph node (with no visceral metastases), any lung metastases (but no liver), and any liver metastases.

    Next: Highest median survival occurred in lymph node-only group

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available